: Most comprehensive health insurance plans in the UAE cover Avastin, but it is essential to check for prior authorization requirements with your provider.

Several factors can affect the price of Avastin in the UAE, including:

The patent for Avastin has expired in many jurisdictions, paving the way for —biological products highly similar to the original. In the UAE, the introduction of biosimilars (such as those by major pharmaceutical competitors) is gradually driving the price down. Biosimilars may be priced 15% to 30% lower than the originator brand, offering a more affordable option for patients paying out of pocket.

Note: These prices exclude VAT (5%) and administration fees (nurse/doctor fees for infusion).

Most comprehensive health insurance plans in the UAE cover Avastin for approved oncological uses, though "off-label" eye treatments may require specific approval or may not be covered at all.

The estimated retail price is approximately AED 2,767.50 .

A long-standing institution in Dubai providing various therapeutic injections, including bevacizumab for eye and oncology care . Important Considerations

Avastin, also known as bevacizumab, is a medication used to treat various types of cancer, including colorectal, lung, breast, and kidney cancer. It works by inhibiting the growth of blood vessels that feed the tumor, thereby slowing down its growth and spread. In the UAE, Avastin is widely used to treat cancer patients, but its price can be a significant concern for many.

The price of Avastin in the UAE can be a significant concern for cancer patients. While the cost of Avastin may seem high, there are ways to make it more affordable. By understanding the factors that affect its price and exploring possible cost-saving options, patients can access this life-saving medication without breaking the bank.

For patients battling cancer or certain eye diseases, Avastin (generic name: Bevacizumab) is often a lifeline. Developed by Roche/Genentech, this biologic medication works by inhibiting vascular endothelial growth factor (VEGF), effectively cutting off the blood supply that tumors need to grow.

The UAE market is shifting aggressively toward biosimilars. In 2025, the DHA issued a circular encouraging prescribers to use biosimilars as first-line therapy unless clinically contraindicated.

Prices may vary slightly between major hospital groups like NMC Healthcare and Saudi German Hospital, often depending on additional administration and consultation fees.